Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6 ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in ...

Treatment Response with Tocilizumab Versus Placebo in Patients with Rheumatoid Arthritis According to the American College of Rheumatology (ACR) Criteria [20] Anthony Sebba, M.D., is Assistant ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

The empirical dietary inflammatory pattern (EDIP) score, used in the study to measure the inflammatory potential of patients' ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply reducing levels of C-reactive protein (CRP), a biomarker for cardiovascular ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

This five-year analysis of the C-144-01 trial represents unprecedented durability and duration of follow-up in advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where ...

Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for reducing the risk of cardiovascular problems in CKD who have ...